FINWIRES · TerminalLIVE
FINWIRES

Stria Lithium Provides Update on Proposed Royalty and Change of Business Transaction

By

Stria Lithium (SRA.V) continues to advance the various components needed under TSX Venture Exchange (TSXV) Policy 5.2 - Changes of Business and Reverse Takeovers, regarding the proposed acquisition of a net smelter return royalty of up to 2% on the advanced West Australian Mt Henry Gold Project pursuant to an investment agreement with Alicanto Minerals (ASX: AQI), it said on Friday.

Work related to the acquisition, including technical reporting, preparation of a listing statement, preparation of transaction documentation, and assembly of required regulatory filings, is progressing as expected, it said.

Stria will hold an annual and special meeting of shareholders on June 9 to elect the directors of the company that will hold office until the next general meeting of the company or completion of the acquisition and approve the change of name of the company to Arc Mineral Royalties Ltd.

The company's shares last traded April 8, closing at $0.78 on the TSXV.

Related Articles

Mining & Metals

Soma Gold Launches Maiden Drill Program at Escondido Project in Colombia

Soma Gold (SOMA.V) has commenced a maiden drill program at the Escondida project in Colombia, the company said Friday.Phase-one drilling comprises 21 drill holes for a total of 2,790 meters, focused on testing the continuity of the mineralized zone near the known mine workings, with 50 m step-outs along strike and down-dip.If phase-one drilling confirms the continuity of the Escondida vein, its associated clay alteration, and gold mineralization, Soma will initiate a phase-two drill program for an additional 3,165 m."We are eager to define the full extent of the Escondida vein and look forward to testing the five additional veins on the property that to date have only ever been worked at surface," said Chris Buchanan, Soma's vice president of exploration.

$SOMA.V
Mining & Metals

Pulsar Helium Acquires Strategic Surface Land at Topaz Helium Project, Minnesota

Pulsar Helium (PLSR.V) has acquired approximately 1,360 acres of surface land in Lake County, Minnesota, located within its flagship Topaz Project, the company said on Friday.The surface land was purchased in an arm's length transaction from Wolf Lands Inc. for total cash consideration of US$2.48 million to be satisfied through the company's existing cash resources, said the company.The newly acquired land lies within the mineral rights that the company holds under lease from a separate private owner, and the area includes the location of the company's Jetstream #7 (JS#7) well, added the company.The acquisition forms part of Pulsar's "broader push toward production readiness at Topaz", said the company and added that it recently concluded its Jetstream exploration and appraisal program, with all wells drilled to date having encountered gas under high pressure and is now obtaining quotes for the drilling of up to four new production wells to supplement two production-ready wells already drilled."This Acquisition, driven by our intention to develop Topaz into a significant primary helium producer, builds on growing momentum at the project as we move decisively toward production readiness," said Thomas Abraham-James, CEO of Pulsar. "It also follows recent legislative progress updating Minnesota's permitting framework for helium extraction. With a clearer pathway now emerging toward future production, securing ownership of the surface land overlying our leased mineral rights, including the site of our Jetstream #7 well, provides Pulsar with increased operational control and long-term development certainty as we continue advancing Topaz toward production."

$PLSR.V
Mining & Metals

Spectral Medical Submits PMX Premarket Approval Application to FDA

Spectral Medical (EDT.TO) has submitted its premarket approval (PMA) application to the U.S. Food and Drug Administration for PMX, the company said on Friday.PMX is Spectral's endotoxin removal therapy for patients with endotoxic septic shock (ESS). The submission is supported by data from the company's Tigris trial, a Phase 3 follow-on study evaluating PMX in patients with ESS. Complete results of the Tigris trial out to 90 days were published last March in the journal The Lancet Respiratory Medicine."This PMA submission represents a defining milestone for Spectral and reflects years of focused clinical, regulatory and operational execution," said chief executive Chris Seto."We believe the totality of evidence supporting PMX demonstrates that a targeted therapy for endotoxic septic shock is beneficial. This is an area of critical unmet medical need with limited therapeutic innovation over the past several decades."Spectral Medical shares closed down $0.02, to $1.40, on Thursday, on the Toronto Stock Exchange.

$EDT.TO